Cryo-Cell International (STU:ZCY) FCF Margin %: 7.62% (As of Feb. 2026) — 53% Below Median


STU:ZCY Cryo-Cell International Inc STU:ZCY
58 GF Score
Price €3.10
GF Value €6.10
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Cryo-Cell International FCF Margin %?

Cryo-Cell International STU:ZCY -2.52% 58 FCF Margin % is 7.62% as of Feb. 2026, which is 53% below its 10-year median of 16.34. GuruFocus rates STU:ZCY with a GF Score™ of 58/100 and a GF Value™ of €6.10 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 666 Healthcare Providers & Services companies, Cryo-Cell International ranks better than 87.39% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cryo-Cell International's Free Cash Flow for the three months ended in Feb. 2026 was €0.50 Mil. Cryo-Cell International's Revenue for the three months ended in Feb. 2026 was €6.50 Mil. Therefore, Cryo-Cell International's FCF Margin % for the quarter that ended in Feb. 2026 was 7.62%.

As of today, Cryo-Cell International's current FCF Yield % is 21.16%.

The historical rank and industry rank for Cryo-Cell International's FCF Margin % or its related term are showing as below:

STU:ZCY' s FCF Margin % Range Over the Past 10 Years
Min: -28.33   Med: 16.34   Max: 25.74
Current: 15.76


During the past 13 years, the highest FCF Margin % of Cryo-Cell International was 25.74%. The lowest was -28.33%. And the median was 16.34%.

STU:ZCY's FCF Margin % is ranked better than
87.39% of 666 companies
in the Healthcare Providers & Services industry
Industry Median: 3.22 vs STU:ZCY: 15.76


Cryo-Cell International FCF Margin % Related Terms


Cryo-Cell International FCF Margin % Historical Data

* Premium members only.

The historical data trend for Cryo-Cell International's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cryo-Cell International FCF Margin % Chart

Cryo-Cell International Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.38 -28.33 4.09 7.52 16.63

Cryo-Cell International Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.19 8.13 31.91 15.48 7.62

STU:ZCY vs CCM, CDIX, EHSI: FCF Margin % Comparison

For the Medical Care Facilities subindustry, Cryo-Cell International's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cryo-Cell International FCF Margin % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Cryo-Cell International's FCF Margin % falls into.


STU:ZCY
58GF Score
Cryo-Cell International Inc STU:ZCY
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cryo-Cell International FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Cryo-Cell International's FCF Margin for the fiscal year that ended in Nov. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Nov. 2025 )/Revenue (A: Nov. 2025 )
=4.54/27.305
=16.63 %

Cryo-Cell International's FCF Margin for the quarter that ended in Feb. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Feb. 2026 )/Revenue (Q: Feb. 2026 )
=0.495/6.5
=7.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 7.62% mean?
Cryo-Cell International (STU:ZCY) has a FCF Margin % of 7.62% as of Feb. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cryo-Cell International and its competitors. This is 53% below median its historical median of 16.34. According to the industry distribution chart, Cryo-Cell International ranks #84 out of 666 companies in the Healthcare Providers & Services industry, placing it in the top 12.6%.
Is Cryo-Cell International's FCF Margin % too high?
Cryo-Cell International's current FCF Margin % of 7.62% is 53% below median its 10-year median of 16.34. The Healthcare Providers & Services industry median FCF Margin % is 3.22. Cryo-Cell International's value of 7.62% is 136.6% above this industry median. Based on the distribution chart, Cryo-Cell International ranks #84 out of 666 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Cryo-Cell International has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's FCF Margin % compare to CCM and CDIX?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #84 out of 666 companies for FCF Margin %. This places Cryo-Cell International in the top 13% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 3.22. Cryo-Cell International's value of 7.62% is 136.6% above this benchmark. While the company's 10-year median is 16.34 vs. the industry median of 3.22, Cryo-Cell International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Healthcare Providers & Services company?
The median FCF Margin % among Healthcare Providers & Services companies is 3.22, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryo-Cell International's current FCF Margin % of 7.62% is 136.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cryo-Cell International and its competitors. For the Healthcare Providers & Services industry, the median FCF Margin % is 3.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryo-Cell International's current FCF Margin % is 7.62%, which is 53% below median its own 10-year median of 16.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (STU:ZCY) is currently considered Possible Value Trap. The stock's GF Value™ is €6.10, compared to a current price of €3.10 — trading 49.2% below its estimated fair value. The current FCF Margin % is 7.62%, which is 53% below median its 10-year median of 16.34 and 136.6% above the Healthcare Providers & Services industry median of 3.22. Cryo-Cell International's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Cryo-Cell International (STU:ZCY), the current FCF Margin % is 7.62% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cryo-Cell International (STU:ZCY) Overvalued in 2026?

Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued. The current stock price of €3.10 is trading 49.2% below its estimated GF Value™ of €6.10. GuruFocus considers Cryo-Cell International to be Possible Value Trap.

Key valuation signals for STU:ZCY:

  • FCF Margin %: 7.62% (53% below median its 10-year median of 16.34)
  • GF Value™: €6.10 vs. price of €3.10 (49.2% below fair value)
  • GF Score™: 58/100 with 5 warning signs
  • Industry Position: 136.6% above the Healthcare Providers & Services median (#84 of 666)

No single metric tells the full story. See the STU:ZCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cryo-Cell International Business Description

Other Exchanges CCEL:USAZCY:Germany
Address 700 Brooker Creek Boulevard, Suite 1800, Oldsmar, FL, USA, 34677
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
58GF Score

Get the complete analysis for STU:ZCY

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.10
Price
€6.10
GF Value